Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Flonoltinib Maleate for the Treatment of Patients With Intermediate- or High-risk Myelofibrosis Who Are Refractory, Relapsed, or Intolerant to JAK Inhibitors: a Single-arm, Open-label, Multicenter Phase IIb Clinical Trial

NCT07443306 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT07443306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07443306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Flonoltinib Maleate for the Treatment of Patients With Intermediate- or High-risk Myelofibrosis Who Are Refractory, Relapsed, or Intolerant to JAK Inhibitors: a Single-arm, Open-label, Multicenter Phase IIb Clinical Trial
Lead sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
March 18, 2026
Completion date
March 30, 2028
Enrollment
64 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mf